Dr. Reddy’s acquires GSK's US penicillin facility and products

Download PDF Copy

Mar 30 2011

Dr. Reddy's Laboratories (NYSE:RDY) today announced the completion of the acquisition of GlaxoSmithKline's (GSK) United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010. As a result of the acquisition, Dr. Reddy's assumes the ownership of the penicillin manufacturing site in Bristol, Tennessee, United States, and rights for the Augmentin® and Amoxil® brands in the United States. GSK will retain the existing rights for these brands outside the United States. Further financial terms and conditions of the transaction are not being disclosed.

Source:

Dr. Reddy's Laboratories

Posted in: Business / Finance | Pharmaceutical News

Tags: GlaxoSmithKline, Manufacturing, Oncology, Pediatrics, Penicillin

Comments (0)

Download PDF Copy

Suggested Reading

New research explores how antimicrobial exposure affects Parkinson’s disease risk

New research explores how antimicrobial exposure affects Parkinson’s disease risk

Targeted bacteriophages offer standardized and scalable GI therapy

Targeted bacteriophages offer standardized and scalable GI therapy

U.S. restaurants face scrutiny over antibiotic policies

U.S. restaurants face scrutiny over antibiotic policies

Researchers discover weakness in bacterial machinery that drives antibiotic resistance

Researchers discover weakness in bacterial machinery that drives antibiotic resistance

New tool spots drug-resistant bacteria before treatment

New tool spots drug-resistant bacteria before treatment

Multiple courses of penicillin antibiotics linked to lower risk of Parkinson's disease

Multiple courses of penicillin antibiotics linked to lower risk of Parkinson's disease

Fish gut bacteria may provide new ingredients for skincare

Fish gut bacteria may provide new ingredients for skincare

Collaborative study offers hope for syphilis vaccine development

Collaborative study offers hope for syphilis vaccine development

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Can probiotics restore antibiotic-perturbed microbiota?